NEUROCRINE BIOSCIENCES INC Operating Lease, Payments
NEUROCRINE BIOSCIENCES INC (NBIX) reported Operating Lease, Payments of $27.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-07-31
- NEUROCRINE BIOSCIENCES INC operating lease, payments for the quarter ending 2026-06-30 was $14.90M, a 58.51% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC operating lease, payments for the quarter ending 2026-03-31 was $12.70M, a 36.56% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC operating lease, payments for the quarter ending 2025-12-31 was $9.60M, a 5.49% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC operating lease, payments for the quarter ending 2025-09-30 was $9.50M, a 5.56% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC operating lease, payments for fiscal 2025 was $37.80M, a 14.20% increase from fiscal 2024.
- NEUROCRINE BIOSCIENCES INC operating lease, payments for fiscal 2024 was $33.10M, a 84.92% increase from fiscal 2023.
- NEUROCRINE BIOSCIENCES INC operating lease, payments for fiscal 2023 was $17.90M, a 5.92% increase from fiscal 2022.
- NEUROCRINE BIOSCIENCES INC operating lease, payments for fiscal 2022 was $16.90M, a 34.13% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $27.60M 10-Q · filed 2026-07-31 | $37.20M derived: sum of 3 quarters · filed 2026-07-31 | $46.70M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $12.70M 10-Q · filed 2026-05-05 | $22.30M derived: sum of 2 quarters · filed 2026-05-05 | $31.80M derived: sum of 3 quarters · filed 2026-05-05 | $41.20M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $9.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $19.10M derived: sum of 2 quarters · filed 2026-02-11 | $28.50M derived: sum of 3 quarters · filed 2026-07-31 | $37.80M 10-K · filed 2026-02-11 |
| 2025-09-30 | $9.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $18.90M derived: sum of 2 quarters · filed 2026-07-31 | $28.20M 10-Q · filed 2025-10-28 | $37.30M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $9.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $18.70M 10-Q · filed 2026-07-31 | $27.80M derived: sum of 3 quarters · filed 2026-07-31 | $36.80M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | $9.30M 10-Q · filed 2026-05-05 | $18.40M derived: sum of 2 quarters · filed 2026-05-05 | $27.40M derived: sum of 3 quarters · filed 2026-05-05 | $36.30M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $9.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $18.10M derived: sum of 2 quarters · filed 2026-02-11 | $27.00M derived: sum of 3 quarters · filed 2026-02-11 | $33.10M 10-K · filed 2026-02-11 |
| 2024-09-30 | $9.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $17.90M derived: sum of 2 quarters · filed 2025-10-28 | $24.00M 10-Q · filed 2025-10-28 | $28.50M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $8.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $15.00M 10-Q · filed 2025-07-30 | $19.50M derived: sum of 3 quarters · filed 2026-02-11 | $24.10M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $6.10M 10-Q · filed 2025-05-05 | $10.60M derived: sum of 2 quarters · filed 2026-02-11 | $15.20M derived: sum of 3 quarters · filed 2026-02-11 | $19.60M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $4.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $9.10M derived: sum of 2 quarters · filed 2026-02-11 | $13.50M derived: sum of 3 quarters · filed 2026-02-11 | $17.90M 10-K · filed 2026-02-11 |
| 2023-09-30 | $4.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $9.00M derived: sum of 2 quarters · filed 2024-10-30 | $13.40M 10-Q · filed 2024-10-30 | $18.10M derived: sum of 4 quarters · filed 2025-02-10 |
| 2023-06-30 | $4.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $8.80M 10-Q · filed 2024-08-01 | $13.50M derived: sum of 3 quarters · filed 2025-02-10 | $17.50M derived: sum of 4 quarters · filed 2025-02-10 |
| 2023-03-31 | $4.40M 10-Q · filed 2024-05-01 | $9.10M derived: sum of 2 quarters · filed 2025-02-10 | $13.10M derived: sum of 3 quarters · filed 2025-02-10 | $17.30M derived: sum of 4 quarters · filed 2025-02-10 |
| 2022-12-31 | $4.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | $8.70M derived: sum of 2 quarters · filed 2025-02-10 | $12.90M derived: sum of 3 quarters · filed 2025-02-10 | $16.90M 10-K · filed 2025-02-10 |
| 2022-09-30 | $4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $8.20M derived: sum of 2 quarters · filed 2023-10-31 | $12.20M 10-Q · filed 2023-10-31 | $15.70M derived: sum of 4 quarters · filed 2024-02-09 |
| 2022-06-30 | $4.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $8.20M 10-Q · filed 2023-08-01 | $11.70M derived: sum of 3 quarters · filed 2024-02-09 | $15.30M derived: sum of 4 quarters · filed 2024-02-09 |
| 2022-03-31 | $4.00M 10-Q · filed 2023-05-03 | $7.50M derived: sum of 2 quarters · filed 2024-02-09 | $11.10M derived: sum of 3 quarters · filed 2024-02-09 | $14.00M derived: sum of 4 quarters · filed 2024-02-09 |
| 2021-12-31 | $3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | $7.10M derived: sum of 2 quarters · filed 2024-02-09 | $10.00M derived: sum of 3 quarters · filed 2024-02-09 | $12.60M 10-K · filed 2024-02-09 |
| 2021-09-30 | $3.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $6.50M derived: sum of 2 quarters · filed 2022-11-01 | $9.10M 10-Q · filed 2022-11-01 | $11.30M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-06-30 | $2.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $5.50M 10-Q · filed 2022-08-04 | $7.70M derived: sum of 3 quarters · filed 2023-02-09 | $9.80M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-03-31 | $2.60M 10-Q · filed 2022-05-04 | $4.80M derived: sum of 2 quarters · filed 2023-02-09 | $6.90M derived: sum of 3 quarters · filed 2023-02-09 | $9.10M derived: sum of 4 quarters · filed 2023-02-09 |
| 2020-12-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $4.30M derived: sum of 2 quarters · filed 2023-02-09 | $6.50M derived: sum of 3 quarters · filed 2023-02-09 | $8.60M 10-K · filed 2023-02-09 |
| 2020-09-30 | $2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | $4.30M derived: sum of 2 quarters · filed 2021-11-01 | $6.40M 10-Q · filed 2021-11-01 | $8.60M derived: sum of 4 quarters · filed 2022-02-11 |
| 2020-06-30 | $2.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $4.30M 10-Q · filed 2021-08-03 | $6.50M derived: sum of 3 quarters · filed 2022-02-11 | $8.70M derived: sum of 4 quarters · filed 2022-02-11 |
| 2020-03-31 | $2.10M 10-Q · filed 2021-05-05 | $4.30M derived: sum of 2 quarters · filed 2022-02-11 | $6.50M derived: sum of 3 quarters · filed 2022-02-11 | $8.20M derived: sum of 4 quarters · filed 2022-02-11 |
| 2019-12-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-11 | $4.40M derived: sum of 2 quarters · filed 2022-02-11 | $6.10M derived: sum of 3 quarters · filed 2022-02-11 | $7.70M 10-K · filed 2022-02-11 |
| 2019-09-30 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $3.90M derived: sum of 2 quarters · filed 2020-11-09 | $5.50M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $1.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-03 | $3.30M 10-Q · filed 2020-08-03 | ||
| 2019-03-31 | $1.60M 10-Q · filed 2020-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |